Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations
Citations Over TimeTop 10% of 2009 papers
Abstract
Nonsense mutations promote premature translational termination and represent the underlying cause of a large number of human genetic diseases. The aminoglycoside antibiotic gentamicin has the ability to allow the mammalian ribosome to read past a false-stop signal and generate full-length functional proteins. However, severe toxic side effects along with the reduced suppression efficiency at subtoxic doses limit the use of gentamicin for suppression therapy. We describe here the first systematic development of the novel aminoglycoside 2 (NB54) exhibiting superior in vitro readthrough efficiency to that of gentamicin in seven different DNA fragments derived from mutant genes carrying nonsense mutations representing the genetic diseases Usher syndrome, cystic fibrosis, Duchenne muscular dystrophy, and Hurler syndrome. Comparative acute lethal toxicity in mice, cell toxicity, and the assessment of hair cell toxicity in cochlear explants further indicated that 2 exhibits far lower toxicity than that of gentamicin.
Related Papers
- → Polyaspartic Acid Prevents Experimental Aminoglycoside Nephrotoxicity(1989)125 cited
- → A Comparison between the Nephrotoxic Profile of Gentamicin and Gentamicin Nanoparticles in Mice(2014)46 cited
- → The effect of gentamicin on calcium uptake by renal mitochondria(1982)41 cited
- → Effect of Cephalothin on Renal Cortical Concentrations of Gentamicin in Rats(1976)34 cited
- → Renal pharmacokinetic changes of gentamicin during enterococcal pyelonephritis(1988)8 cited